Response letter to "Latent class analysis of 216 patients with adult-onset Still's disease" by Sugiyama et al

Arthritis Res Ther. 2022 Dec 28;24(1):285. doi: 10.1186/s13075-022-02984-7.

Abstract

Sugiyama et al. recently described in "Latent class analysis of 216 patients with adult-onset Still's disease," baseline characteristics, laboratory tests, treatment, relapse, and death of adult-onset Still's disease (AOSD) patients from a Japanese hospital. They identified two subgroups: Class 1 (n=155) with a younger age and typical symptoms of AOSD and Class 2 (n=61) with older patients and fewer typical symptoms of AOSD. In 2022, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, an established X-linked disease associated with a somatic mutation in UBA1, is considered as a differential diagnosis for AOSD particularly in elderly. These patients from Class 2 could benefit from more explorations for mild myelodysplasia and VEXAS.

Keywords: Adult-onset Still’s disease; Myelodysplastic syndrome; VEXAS.

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Aged
  • Humans
  • Latent Class Analysis
  • Myelodysplastic Syndromes* / complications
  • Skin Diseases, Genetic
  • Still's Disease, Adult-Onset* / diagnosis
  • Still's Disease, Adult-Onset* / genetics
  • Syndrome

Supplementary concepts

  • VEXAS syndrome